^
Association details:
| Biomarker: | STRN-ALK fusion + KRAS G13D |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Zykadia (ceritinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target
Excerpt:
Based on the STRN–ALK fusion, the patient was treated with ceritinib...after 9 months of treatment, the disease progressed...At that time, the patient underwent a biopsy of a periumbilical metastasis, and posttargeted therapy CGP was performed, which now identified a new KRAS G13D mutation in addition to the STRN–ALK fusion.
DOI:
10.1158/1078-0432.CCR-15-3000
Trial ID:
